PTK2 and Hypercholesterolemia: Previous studies have reported that elevated cholesterol biosynthesis or hypercholesterolemia is closely associated with sorafenib resistance (30), supporting the hypothesis that FAK activation promotes resistance via dysregulation of cholesterol metabolism.